Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Erasca, Inc. (NASDAQ: ERAS). The investigation focuses on Erasca’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Erasca securities?
If you purchased Erasca securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation
On April 27, 2026, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for Revolution Medicines, Inc. alleging, among other things, that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanding that the Company cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.” Erasca stated that it believes the assertions are without merit and intends to contest the allegations vigorously.

Erasca also reported preliminary Phase 1 clinical data for ERAS-0015 in a separate Form 8-K filing. Among other things, the Company reported response-rate data that included both confirmed and unconfirmed responses across patient cohorts of varying sizes. The Company further stated that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were based on cross-study analyses and “not based on any head-to-head clinical trials,” and cautioned that such comparisons are “inherently limited” and “may not be directly comparable.”

Following these disclosures, Erasca’s stock price declined significantly, damaging investors.

In light of this disclosure, Johnson Fistel is investigating whether Erasca complied with the federal securities laws. If you suffered losses from your investment in Erasca stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.